61 Followers on Owler

ReCode Therapeutics

Read more
CEO Avatar

President & CEO

David J. Lockhart

CEO Approval Rating

90/100

Founded:

2015

Status:

PrivateIndependent Company

Est. Annual Revenue
$4.1M
Agree?
Est. Employees
21
Agree?

RECODE THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

ReCode Therapeutics's company profile
CEO Avatar

David J. Lockhart

President & CEO

90/100
21
$82M
$4.1M
View Profile
1
ReCode Therapeutics's Competitor - PTC Therapeutics logo
Stuart W. Peltz's photo - Founder & CEO of PTC Therapeutics

Stuart W. Peltz

Founder & CEO

96/100
517
$426.6M
$471.9M
View Profile
2
ReCode Therapeutics's Competitor - Breath Therapeutics logo
Jens Stegemann's photo - Co-Founder & CEO of Breath Therapeutics

Jens Stegemann

Co-Founder & CEO

90/100
57
$48.6M
$3M
View Profile
3
ReCode Therapeutics's Competitor - MediciNova logo
Yuichi Iwaki's photo - President & CEO of MediciNova

Yuichi Iwaki

President & CEO

89/100
9
$232.5M
$16M
View Profile
4
ReCode Therapeutics's Competitor - Synairgen logo
Richard Marsden's photo - CEO of Synairgen

Richard Marsden

CEO

79/100
14
$149.2M
$6.3M
View Profile
5
ReCode Therapeutics's Competitor - Dicerna logo
Douglas M. Fambrough's photo - President & CEO of Dicerna

Douglas M. Fambrough

President & CEO

85/100
78
$478M
$178.8M
View Profile
6
ReCode Therapeutics's Competitor - Verona Pharma logo
David Zaccardelli's photo - President & CEO of Verona Pharma

David Zaccardelli

President & CEO

86/100
25
$348.5M
View Profile
7
ReCode Therapeutics's Competitor - Sarepta logo
Douglas S. Ingram's photo - President & CEO of Sarepta

Douglas S. Ingram

President & CEO

84/100
499
$942.3M
$600.1M
View Profile
8
ReCode Therapeutics's Competitor - Cydan logo
Chris Adams's photo - Co-Founder & CEO of Cydan

Chris Adams

Co-Founder & CEO

88/100
25
$81.6M
$5M
View Profile
9
ReCode Therapeutics's Competitor - Enterprise Therapeutics logo
John Ford's photo - CEO of Enterprise Therapeutics

John Ford

CEO

87/100
30
$59M
$7M
View Profile
10
ReCode Therapeutics's Competitor - FibroGen logo
Enrique Conterno's photo - CEO of FibroGen

Enrique Conterno

CEO

90/100
461
$145.8M
$171.8M
View Profile
11
ReCode Therapeutics's Competitor - Xencor logo
Bassil I. Dahiyat's photo - President & CEO of Xencor

Bassil I. Dahiyat

President & CEO

85/100
156
$239.6M
$178.6M
View Profile
12
ReCode Therapeutics's Competitor - Sangamo logo
Sandy Macrae's photo - President & CEO of Sangamo

Sandy Macrae

President & CEO

77/100
302
$71.5M
$137.7M
View Profile

Missing a competitor? Contribute!

PTC Therapeutics is perceived as one of ReCode Therapeutics's biggest rivals. PTC Therapeutics is headquartered in South Plainfield, New Jersey, and was founded in 1998. Like ReCode Therapeutics, PTC Therapeutics also operates in the Biotechnology industry. PTC Therapeutics generates 11,509% the revenue of ReCode Therapeutics.

Breath Therapeutics is one of ReCode Therapeutics's top competitors. Breath Therapeutics is a Private company that was founded in 2016 in Munich, Bavaria. Like ReCode Therapeutics, Breath Therapeutics also operates in the Biotechnology field. Compared to ReCode Therapeutics, Breath Therapeutics has 36 more employees.

MediciNova has been one of ReCode Therapeutics's top competitors. MediciNova was founded in 2000 in La Jolla, California. Like ReCode Therapeutics, MediciNova also works within the Biotechnology field. MediciNova generates $11.9M more revenue than ReCode Therapeutics.

ReCode Therapeutics Acquisitions

No recent acquisitions found related to ReCode Therapeutics

ReCode Therapeutics Funding History

Since ReCode Therapeutics was founded in 2015, it has participated in 2 rounds of funding. In total ReCode Therapeutics has raised $82.0M. ReCode Therapeutics' last funding round was on Mar 2020 for a total of $80.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Mar 2020
$80M
Seed
Dec 2016
$2M
-

Since ReCode Therapeutics was founded in 2015, it has participated in 2 rounds of funding. In total ReCode Therapeutics has raised $82.0M. ReCode Therapeutics' last funding round was on Mar 2020 for a total of $80.0M

ReCode Therapeutics Investments

No recent investments found related to ReCode Therapeutics

ReCode Therapeutics News

June 14, 2021MarketScreener

to Participate in Upcoming June Investor Conferences

(marketscreener.com) ReCode Therapeutics , a biopharmaceutical company pioneering disease-modifying g... See more »
June 11, 2021MarketScreener

Presents Preclinical Data Using SORT-LNP and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)

(marketscreener.com) Company's powerful Lipid Nanoparticle platform delivers tRNA and mRNA and demons... See more »
May 24, 2021MarketScreener

to Present Preclinical Data Using SORT-LNP and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)

(marketscreener.com) ReCode Therapeutics , a biopharmaceutical company pioneering disease-modifying m... See more »
February 17, 2021MarketScreener

to Participate in Upcoming Investor Conferences

(marketscreener.com) ReCode Therapeutics , a private biopharmaceutical company pioneering disease-mod... See more »
March 28, 2020Dallas Innovates

ReCode Therapeutics Gets $80M Investment for Lung Disease Drugs

Dallas Innovates, Every Day: Here's what's new + next in North Texas.Dallas biopharmaceutical company... See more »
March 25, 2020BioPortfolio

With $80M ReCode Looks to Advance RNA Therapies for Lung Diseases

Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $... See more »
March 25, 2020The Business Journals: San Francisco Business Times

How Bay Area and Texas startups merged, raised $80M and breathed new hope into fight against lung diseases

As TranscripTx Inc. CEO David Lockhart helped two of his company's investors evaluate a Texas startup... See more »

ReCode Therapeutics Press Releases

Social Media

ReCode Therapeutics Headquarters

1455 Adams Dr

Menlo Park, California94025

408-585-1718

Driving Directions »

Trending Companies

ReCode Therapeutics Summary

ABOUT

Overview

ReCode is a biopharmaceutical company that develops precision medicines for the treatment of pulmonary diseases. ReCode Therapeutics was founded in 2015. ReCode Therapeutics' headquarters is located in Menlo Park, California, USA 94025. It has raised ...

CEO

ReCode Therapeutics's President & CEO, David J. Lockhart, currently has an approval rating of 90%. ReCode Therapeutics's primary competitors are PTC Therapeutics, Breath Therapeutics & MediciNova.

Frequently Asked Questions about ReCode Therapeutics

  1. When was ReCode Therapeutics founded?

    ReCode Therapeutics was founded in 2015
  2. Who is ReCode Therapeutics's CEO?

    ReCode Therapeutics's CEO is David J. Lockhart
  3. How much revenue does ReCode Therapeutics generate?

    ReCode Therapeutics generates $4.1M in revenue
  4. How much funding does ReCode Therapeutics have?

    ReCode Therapeutics has historically raised $82M in funding
  1. Where is ReCode Therapeutics's headquarters?

    ReCode Therapeutics's headquarters is in Menlo Park California, USA
  2. How many employees does ReCode Therapeutics have?

    ReCode Therapeutics has 21 employees
  3. What sector does ReCode Therapeutics operate in?

    ReCode Therapeutics is in Biotechnology
  4. Who are ReCode Therapeutics's competitors?

    ReCode Therapeutics's top competitors are PTC Therapeutics, Breath Therapeutics, MediciNova